WINNIPEG, MANITOBA (MARKET WIRE) DiaMedica (TSX VENTURE: DMA) is pleased to announce the company's entry into an evaluation agreement with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health (NIH), to further evaluate its monoclonal antibody (mAb), in a pre-clinical model, for the treatment of tularemia, a serious infectious disease caused by the Francisella tularensis bacteria. F. tularensis is classified as a Class A bioweapon due to being highly infectious when in aerosol form. The US Center for Disease Control (CDC) examined the total base cost to